0001912966 1 2026-08-09 2026-08-09 0001912966 2 2026-08-09 2026-08-09 0001912966 3 2026-08-09 2026-08-09 0001912966 2026-08-09 2026-08-09 iso4217:USD pure shares S-8 EX-FILING FEES 0001912966 false false false N/A S-8 Regentis Biomaterials Ltd. Equity Ordinary Shares, no par value per share, reserved for issuance pursuant to the 2024 Share Option Plan true 500000 1.9475 973750.00 0.0001381 134.47 Equity Ordinary Shares, no par value per share, reserved for issuance pursuant to options outstanding under the 2024 Share Option Plan true 1150132 1.9475 2239882.07 0.0001381 309.33 Equity Ordinary Shares, no par value per share, reserved for issuance pursuant to options outstanding under the 2009 Share Incentive Plan true 41790 1.9475 81386.03 0.0001381 11.24 3295018.10 455.04 0.00 455.04 Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also includes an indeterminate number of additional shares that become issuable under the 2024 Share Option Plan and the 2009 Share Incentive Plan as a result of anti-dilution provisions described therein by reason of any dividend, share split, recapitalization or other similar transaction effected without the receipt of consideration leading to an increase in the number of outstanding shares.<br/><br/>Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act, based upon the average of the high ($2.04) and low ($1.855) sales prices of the registrant’s ordinary shares as reported on the NYSE American on August 7, 2026. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also includes an indeterminate number of additional shares that become issuable under the 2024 Share Option Plan and the 2009 Share Incentive Plan as a result of anti-dilution provisions described therein by reason of any dividend, share split, recapitalization or other similar transaction effected without the receipt of consideration leading to an increase in the number of outstanding shares. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also includes an indeterminate number of additional shares that become issuable under the 2024 Share Option Plan and the 2009 Share Incentive Plan as a result of anti-dilution provisions described therein by reason of any dividend, share split, recapitalization or other similar transaction effected without the receipt of consideration leading to an increase in the number of outstanding shares.